Anti-Human CXCR4 [12G5] In Vivo Antibody - Low Endotoxin
Introducing the Anti-Human CXCR4 [12G5] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications. This antibody targets the CXCR4 protein, an essential chemokine receptor involved in various cellular processes, making it ideal for research in immunology, oncology, and related fields. With a mouse IgG2a kappa isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), perfect for ELISA, flow cytometry, immunohistochemistry, and other assays.
Available in various sizes, it is formulated in phosphate-buffered saline for stability and efficacy. Enhance your research with this reliable and versatile antibody. CXCR4 is a G protein-coupled receptor expressed on the surface of various cells including immune cells, stem cells, and cancer cells. It plays a significant role in immune cell trafficking, HIV infection, and cancer metastasis by binding to its ligand, stromal cell-derived factor-1 (SDF-1).
Product Name:
Anti-Human CXCR4 (Clone 12G5) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0266
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
12G5
Protein:
CXCR4
Product Type:
Monoclonal Antibody
Synonyms:
Fusin, LESTR, CD184
Isotype:
IgG2a k
Reactivity:
Human
Applications:
B, FC, ICC, IF Microscopy, IHC, In Vivo, N, WB
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FC, ICC, IF Microscopy, IHC, In Vivo, N, WB
Reactivity:
Human
Host Species:
Mouse
Specificity:
12G5 activity is directed against human CXCR4 (CD184; Fusin).
Antigen Distribution:
CXCR4 is expressed in various organs including ovary, bone marrow, kidney, lung, small intestine, spleen, lymph nodes, brain, stomach, liver, thymus, heart, and pancreas as well as on the surface of endothelial mature and precursor cells and pericytes.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.
CXCR4 is a G-protein coupled receptor that binds the chemokine CXCL121. Chemokines are small 8-12 kDa proteins that mediate cell migration and arrest, homing and trafficking of leukocytes in bone marrow and lymphoid organs, tissue formation, cytoskeletal rearrangement, and immune cell recruitment to inflammation. Additionally, chemokines are expressed by cancer cells, where they enhance tumor angiogenesis and development. CXCR4 is the chemokine receptor most abundantly expressed2 and most frequently detected3 in various cancer types, being present in malignant cell subpopulations in primary tumors as well as sites of metastasis. CXCR4 is involved in tumor cell proliferation and migration2 and is involved in leukocyte chemotaxis in several autoimmune diseases1. CXCR4 also acts as an alternative receptor for some isolates of HIV-2 in the absence of CD44. CXCR4 expression is regulated by HIF-1α, IL-5, IFN-gamma, TGF-β, and IL-17A1.
12G5 was produced by immunizing Balb/c mice with CP-MAC-infected Sup-T1 cells4. Hybridomas were generated and screened for the ability to inhibit CP-MAC-induced syncytium induction on Sup-T1 cells.
12G5 binds specifically to both human and nonhuman cells that express recombinant CXCR44. 12G5 inhibits CD4-independent infection by some HIV-2 isolates, and preincubating cells with 12G5 abolishes syncytium formation. HIV-2/vcp-infected cells display a marked and selective reduction in 12G5 binding. 12G5 also inhibits induction of cell-to-cell fusion of CXCR4+ RD/CD4 cells by HIV-1 and HIV-2 strains5.
